Picture loading failed.

Anti-CD27 therapeutic antibody (Pre-made Varlilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Varlilumab (INN; development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-614-1mg 1mg 3090
GMP-Bios-ab-614-10mg 10mg 21890
GMP-Bios-ab-614-100mg 100mg 148000
GMP-Bios-ab-614-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD27 therapeutic antibody (Pre-made Varlilumab biosimilar,Whole mAb)
INN Name Varlilumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesCelldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia
Conditions Approvedna
Conditions ActiveMalignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma
Conditions DiscontinuedHaematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma
Development Techna